Renibus Therapeutics, Inc.
Small molecule therapeutics for cardiorenal diseases
- Sector
- Biotech
- Headquarters
- SOUTHLAKE, TX
- Founded
- 2015
- Latest Form D
- $63.8M, Jun 2023
- Total capital
- $85.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $85.3M
- 5 Form D · last Jun 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2022
- Rank in peer group#156 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$63.8M
- Private capital raisedForm D · SEC · 4th filing$14.9M
- Private capital raisedForm D · SEC · 3rd filing$3.4M
- Private capital raisedForm D · SEC · 2nd filing$2.9M
- Private capital raisedForm D · SEC · 1st filing$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#156 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alvaro GuillemExecutive Officer, DirectorNamed in SEC Form D filings
- Bhupinder Jeffrey SinghExecutive Officer, DirectorNamed in SEC Form D filings
- Carlos GuillemDirectorNamed in SEC Form D filings
- Dale JonesDirectorNamed in SEC Form D filings
- D. Jeffrey KeyserExecutive Officer, DirectorNamed in SEC Form D filings
- Frank Jeffrey StonebanksExecutive Officer, DirectorNamed in SEC Form D filings
Show all 12 people
- Harpreet KaurExecutive Officer, DirectorNamed in SEC Form D filings
- Henrik Jeffrey RasmussenDirectorNamed in SEC Form D filings
- Jamie Jeffrey DonadioExecutive OfficerNamed in SEC Form D filings
- Jennifer D. RasmussenDirectorNamed in SEC Form D filings
- Jocelyn D. KeyserDirectorNamed in SEC Form D filings
- Nels D. BergmarkExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- GrantedNovel Tetrahydrocurcumin Compositions, Methods Of Making, And Methods Of Using The SameUSPTOUS 12,697,311
- PendingMethod For Treatment Of Coronavirus InfectionUSPTOApplication 19181034
- PendingCompositions of Stannic Protoporfin for Long Term Stability and Container Closure Systems for Storing Stannic ProtoporfinUSPTOApplication 19413414
Show all 40 patent records
- Novel Tetrahydrocurcumin Compositions, Methods Of Making, And Methods Of Using The SameAug 4, 2026 · US 12,697,311Granted
- Method For Treatment Of Coronavirus InfectionJun 11, 2026 · Application 19181034Pending
- Compositions of Stannic Protoporfin for Long Term Stability and Container Closure Systems for Storing Stannic ProtoporfinJun 11, 2026 · Application 19413414Pending
- Hcl-binding Compositions For And Methods Of Treating Acid-base DisordersJun 2, 2026 · US 12,642,815Granted
- Novel Stannic Protoporfin Compositions, Methods of Making, and Uses ThereofJul 31, 2025 · Application 18428728Pending
- Method Of Treating Acid-base DisordersJul 10, 2025 · Application 19004279Pending
- Stress Test And Treatment Of Chronic Kidney DiseaseMay 22, 2025 · Application 18959858Pending
- Compositions For And Method Of Treating Acid-base DisordersJan 23, 2025 · Application 18632554Pending
- Novel Tetrahydrocurcumin Compositions, Methods Of Making, And Methods Of Using The SameJan 16, 2025 · Application 18884250Pending
- Stress Test And Treatment Of Chronic Kidney DiseaseDec 31, 2024 · US 12,178,789Granted
- Metal Protoporphyrin For Treatment Of Bk VirusOct 17, 2024 · Application 18747522Pending
- Novel Tetrahydrocurcumin Compositions, Methods Of Making, And Methods Of Using The SameOct 15, 2024 · US 12,115,138Granted
- Metal Protoporphyrin For Treatment Of Bk VirusJul 23, 2024 · US 12,042,501Granted
- Methods Of Protecting An Organ Prior To Surgery In Patients Susceptible To Post-operative Complications Including PhotosensitivityJul 11, 2024 · Application 18407130Pending
- Novel Stannic Protoporfin Compositions, Methods of Making, and Uses ThereofMay 23, 2024 · Application 18363548Pending
- Methods Of Treating Patients At Risk For Renal Injury And Renal FailureApr 23, 2024 · US 11,965,896Granted
- Stress Test And Treatment Of Chronic Kidney DiseaseJan 30, 2024 · US 11,883,371Granted
- Novel Iron Compositions And Methods Of Making And Using The SameJan 4, 2024 · Application 18243584Pending
- Novel Iron Compositions And Methods Of Making And Using The SameDec 12, 2023 · US 11,840,552Granted
- Novel Iron Compositions And Methods Of Making And Using The SameDec 5, 2023 · US 11,834,471Granted
- Methods Of Treating Patients At Risk For Renal Injury And Renal FailureSep 6, 2022 · US 11,435,364Granted
- Novel Iron Compositions And Methods Of Making And Using The SameApr 5, 2022 · US 11,292,813Granted
- Method For Treating Cancer With Kidney ProtectionMar 17, 2022 · Application 17472954Pending
- Method For Treatment Of Coronavirus InfectionNov 4, 2021 · Application 17205521Pending
- Compositions For Treating Acid-base DisordersJul 8, 2021 · Application 17192701Pending
- Method Of Treating Acid-base DisordersApr 15, 2021 · Application 17111141Pending
- Methods For Treating Renal Injury By Therapeutically Upregulating P21Jun 4, 2020 · Application 16697808Pending
- Novel Iron Compositions And Methods Of Making And Using The SameApplication 62812028Pending
- Methods For Treating Renal Injury By Therapeutically Upregulating P21Application 62773743Pending
- Methods Of Treating Patients At Risk For Renal Injury And Renal FailureApplication 62715508Pending
- Compositions Of Stannic Protoporfin For Long Term Stability And Container Closure Systems For Storing Stannic ProtoporfinApplication PCTUS2025058759Pending
- Methods Of Treating Patients At Risk For Renal Injury And Renal FailureApplication 62676157Pending
- Compositions of Stannic Protoporfin for Long Term Stability and Container Closure Systems for Storing Stannic ProtoporfinApplication 63729911Pending
- Novel Stannic Protoporfin Compositions, Methods Of Making, And Uses ThereofApplication PCTUS2024013764Pending
- Methods Of Protecting An Organ Prior To Surgery In Patients Susceptible To Post-operative Complications Including PhotosensitivityApplication PCTUS2024010739Pending
- Methods Of Protecting An Organ Prior To SurgeryApplication 63602216Pending
- Methods Of Protecting An Organ Prior To SurgeryApplication 63601700Pending
- Methods Of Protecting An Organ Prior To SurgeryApplication 63595699Pending
- Methods Of Protecting An Organ Prior To SurgeryApplication 63499974Pending
- Methods Of Protecting An Organ Prior To SurgeryApplication 63478975Pending
Related companies, and why
- Endeavor BioMedicinesSimilar federal contract value in Biotech · null in contracts
- AbsciSimilar federal contract value in Biotech · null in contracts
- Generation BioSimilar federal contract value in Biotech · null in contracts
- Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Revolution MedicinesSimilar federal contract value in Biotech · null in contracts
- NovaBay PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .